High Expression Confers Poor Prognosis in Colorectal Cancer, and Represents a Novel Therapeutic Target in BRAF-Mutated Colorectal Cancer.

We aimed to investigate the role of expression in colorectal cancer (CRC) prognosis and evaluate its potential as a therapeutic target in -mutated CRC. : Exactly 136 samples of formalin-fixed paraffin-embedded CRC tissue specimens were obtained from patients who underwent surgical resection for CRC. The gene mutation status of the samples was detected using fluorescence PCR. expression was detected using immunohistochemistry. Survival curves with high expression and mutations were compared using the Kaplan-Meier method. A nomogram was constructed to determine the estimated overall survival probability. We also predicted the 3-year and 5-year survival rates for patients with high expression and mutations. In total, 50 samples of -mutated CRC were collected and detected expression by immunohistochemistry. The Chi-squared test was used to analyze the association between expression and -mutated CRC. : High expression and mutations are associated with poor prognosis of CRC. Multivariate survival analyses indicated that high expression and mutations are significant independent predictors of CRC prognosis. Furthermore, high expression was significantly associated with -mutated CRC, and may be a potential therapeutic target for -mutated CRC. : High expression confers poor prognosis in colorectal cancer and represents a novel therapeutic target in -mutated CRC.